Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT

Nuclear Medicine Communications

Volumn 31, Issue 12, 2010, Pages 1016-1024

  Doss, Mohan ^a   Zhang, James J ^c   Bélanger, Marie José ^b   Stubbs, James B ^d   Hostetler, Eric D ^b   Alpaugh, Katherine ^a   Kolb, Hartmuth C ^c   Yu, Jian Q ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SIEMENS CORPORATE RESEARCH   (United States)

^d Radiation Dosimetry Systems Inc   (United States)

Author keywords

18F HX4; biodistribution; hypoxia marker; positron emission tomography; radiation dosimetry

Indexed keywords

FLUORO 2 [4 [(2 NITRO 1H IMIDAZOL 1 YL)METHYL] 1H 1,2,3 TRIAZOL 1 YL]PROPAN 1 OL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER; COMPUTER PROGRAM; CONTROLLED STUDY; DOSIMETRY; DRUG ELIMINATION; FEMALE; HUMAN; KIDNEY; LIVER; MALE; MEAN RESIDENCE TIME; MICTURITION; NONHUMAN; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RHESUS MONKEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY CT;

ANIMALS; ANOXIA; BIOLOGICAL MARKERS; FEMALE; HAPLORHINI; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS; SPECIES SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES; WHOLE BODY IMAGING;

EID: 78649319950     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283407950     Document Type: Article

References (20)

1. Lucignani G. PET imaging with hypoxia tracers: a must in radiation therapy. Eur J Nucl Med Mol Imaging 2008; 35:838-842.
2. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006; 82:699-757.
3. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008; 13 (Suppl 3):21-26.
4. Zeng L, Ou G, Itasaka S, Harada H, Xie X, Shibuya K, et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 2008; 99:2327-2335.
5. Zaffaroni N, Fiorentini G, De Giorgi U. Hyperthermia and hypoxia: new developments in anticancer chemotherapy. Eur J Surg Oncol 2001; 27:340-342.
6. Yamazaki Y, Kunimoto S, Ikeda D. Rakicidin A: a hypoxia-selective cytotoxin. Biol Pharm Bull 2007; 30:261-265.
7. Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006; 33 (Suppl 1):44-53.
8. Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009; 36:1674-1686.
9. Graham MM, Peterson LM, Link JM, Evans ML, Rasey JS, Koh WJ, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med 1997; 38:1631-1636.
10. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed Engl 2001; 40:2004-2021.
11. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective 'ligation' of azides and terminal alkynes. Angew Chem Int Ed Engl 2002; 41:2596-2599.
12. Tornoe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem 2002; 67:3057-3064.
13. 18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010; 37:1663-1668.
14. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46:1023-1027.
15. Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 1998; 47:484-492.
16. Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys 1973; 25:147-161.
17. 18F-CPFPX determined from human whole-body PET. Eur J Nucl Med Mol Imaging 2008; 35:1499-1506.
18. Stabin M, Stubbs J, Toohey R. Radiation Dose Estimates from Radiopharmaceuticals, Report NUREG/CR-6345 prepared for US Nuclear Regulatory Commission by Oak Ridge Institute for Science and Education, Oak Ridge, TN, 1996. URL: http://www.nrc.gov/reading-rm/doc-collections/nuregs/contract/cr6345/ cr6345.pdf
19. 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med 2002; 43:1674-1680.
20. 18F]fluoro-2-deoxy-D-glucose in adult humans. J Nucl Med 1991; 32:707-712.